Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 93 clinical trials
Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292).

A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor

  • 0 views
  • 24 May, 2021
  • 12 locations
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

the combination of Fulvestrant plus Palbociclib as neoadjuvant therapy of hormone-sensitive patients with operable luminal breast cancer. Eligible patients will be assessed upfront using the

adjuvant therapy
palbociclib 125 mg
palbociclib
serum calcium
fulvestrant
  • 161 views
  • 22 Jan, 2021
  • 14 locations
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib

  • 0 views
  • 27 Jan, 2021
  • 1 location
Palbociclib Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

This study is investigating the combination of palbociclib, letrozole and venetoclax in ER and BCL-2 positive locally advanced or metastatic breast cancer. It is hypothesised that

metastasis
neutrophil count
palbociclib
mirena
cancer
  • 45 views
  • 24 Jan, 2021
  • 3 locations
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+ HER2- Advanced Breast Cancer Patients (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.

HER2
metastasis
her2-negative breast cancer
aromatase inhibitor
progesterone
  • 0 views
  • 18 Apr, 2021
  • 49 locations
Adjuvant Palbociclib in Elderly Patients With Breast Cancer

Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by

HER2
taxane
core needle biopsy
cyclophosphamide
estrogen receptor
  • 4 views
  • 15 May, 2021
  • 73 locations
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improvesprogression free survival (PFS) when compared with letrozole in combination with

metastasis
HER2
palbociclib
erbb2
letrozole
  • 0 views
  • 13 Jun, 2021
  • 194 locations
High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

This is a phase II, multi-center, single-arm, open-label trial to evaluate efficacy of palbociclib with endocrine therapy as adjuvant treatment in women with C-high/G-high risk ER-positive/HER2

HER2
mammogram
erbb2
immunostimulant
breast-conserving surgery
  • 0 views
  • 24 Jan, 2021
  • 1 location
Randomized Open Label Clinical Study of the Targeted Therapy Palbociclib to Treat Metastatic Breast Cancer

The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine

HER2
palbociclib
targeted therapy
fulvestrant
neutrophil count
  • 544 views
  • 27 Jan, 2021
  • 132 locations
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)

HER2
mammogram
palbociclib
erbb2
immunostimulant
  • 63 views
  • 27 Jan, 2021
  • 67 locations